Aumolertinib improved progression-free survival vs placebo in patients with unresectable stage III non–small cell lung cancer ...

Jacob Stein, MD, MPH, discusses how nab-sirolimus improves outcomes for patients with advanced perivascular epithelioid cell tumors compared with other treatments or no treatment options.

During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed CAR T-cell therapy as third-line therapy for ...

Noah S. Kalman, MD, MBA, discusses the most common types of thyroid cancer and their respective prognosis.

In an interview with Targeted Oncology, Erika Hamilton, MD, discussed emerging endocrine therapies that are advancing breast ...

The FDA accepted the new drug application for TLX101-CDx and granted priority review to the agent in glioma. The FDA has ...

Panelist discusses how agents such as osimertinib, initially developed to target resistance mechanisms in refractory disease, ...

John Seymour, MD, discusses the development and clinical application of BCL-2 inhibitors for the treatment of CLL.

Recent advancements in protein engineering, especially antibody-drug conjugates, show promise in lung cancer treatment, with ...

Based Roundtable® event, Yazan Madanat, MD, discussed a the patient population and outcomes of the COMMANDS trial of ...

Tanya Gupta, MD, discusses the use of ado-trastuzumab emtansine for the treatment of patients with HER2-positive breast ...

Rebecca A. Shatsky, MD, discussed the I-SPY2.2 trial, its novel design, and its implications for the treatment of patients ...